CD19-ReTARGTPR: Redirecting Pre-existing Anti-CMV Immunity against CD19-Expressing Malignancies through Physiologic TCR Engagement
Key Points
- A monomeric fusion protein, CD19-ReTARGTPR, was engineered to redirect pre-existing anti-cytomegalovirus (CMV) CD8+ cytotoxic T lymphocyte (CTL) responses toward CD19-expressing B-cell malignancies.
- By engaging T-cell receptors (TCRs) through physiologic peptide-HLA class I (pHLA-I) interactions, this approach circumvents the T-cell hyperactivation and supraphysiologic cytokine release characteristic of chimeric antigen receptor (CAR)-T cell and bispecific T-cell engager (BiTE) therapies.
- CD19-ReTARGTPR mediated potent target cell lysis across a panel of CD19-positive hematologic cancer cell lines and primary chronic lymphocytic leukemia (CLL) cells, including clones with low CD19 antigen density that were resistant to blinatumomab and CD19-CAR-T cells.
- Interferon-γ secretion was reduced ~100-fold relative to blinatumomab and ~400-fold relative to CD19-CAR-T cells, with concomitant decreases in interleukin-6 and tumor necrosis factor-α---cytokines central to cytokine release syndrome (CRS) pathogenesis.
- Activation-induced cell death (AICD) in effector CTLs was minimal (~10% increase in apoptosis) compared with CD19-CAR-T cells (~40% increase), suggesting enhanced effector persistence.
Background and Rationale
Adoptive immunotherapies targeting CD19 have transformed the management of B-cell malignancies. However, both CAR-T cells and BiTEs bypass cognate TCR/pHLA-I signaling, resulting in uncontrolled T-cell hyperactivation. This nonphysiologic activation drives excessive proinflammatory cytokine release, manifesting clinically as CRS in >70% of patients receiving CD19-CAR-T therapy, and predisposes effector cells to AICD, thereby limiting therapeutic persistence.
In contrast, physiologic CTL activation via TCR-pHLA-I engagement is tightly regulated by layered negative feedback mechanisms (PAG, SHP-1, PTEN, DGKs), ensuring precise target elimination without bystander damage. Immunotherapeutic platforms that preserve this natural axis may thus achieve comparable antitumor efficacy with improved safety profiles.
Harnessing Anti-CMV Memory T Cells
In CMV-seropositive individuals, inflationary CD8+ T cells specific for immunodominant CMV antigens---notably the HLA-B*07:02-restricted pp65-derived peptide TPRVTGGAM (TPR)---frequently constitute >10% of the peripheral CTL repertoire. These cells retain robust cytotoxic function, effector-memory phenotype, and broad tissue-homing capacity, including tumor microenvironment infiltration. Critically, in CLL patients, whose autologous tumor-reactive T cells are typically exhausted, anti-CMV CTLs remain functionally competent, rendering them an attractive effector pool for redirection strategies.
Molecular Design and Mechanism of Action
CD19-ReTARGTPR comprises three covalently linked domains: (i) the TPR peptide, (ii) a soluble HLA-B*07:02/β2-microglobulin complex, and (iii) a high-affinity anti-CD19 Fab fragment derived from tafasitamab (MOR208). Upon binding to CD19 on malignant B cells, the fusion protein presents synthetic TPR-pHLA-I complexes on the tumor surface, enabling engagement by cognate TCRs on anti-CMV CTLs and triggering classical TCR/CD3 signaling with intact downstream regulatory checkpoints---mechanisms that are circumvented by CAR-T and BiTE architectures.
Purified CD19-ReTARGTPR exhibited an apparent molecular weight of ~95 kDa under non-reducing conditions, consistent with its calculated mass of 96.9 kDa; under reducing conditions, the protein resolved into ~70 kDa and ~25 kDa bands corresponding to the heavy chain and Fab light chain, respectively
Flow cytometry confirmed dose-dependent, CD19-selective binding to CHO.CD19 and SEM cells, with no detectable binding to parental CD19-negative CHO cells. This binding was competitively inhibited by excess anti-CD19 mAb MOR208 but not by rituximab, confirming CD19-specific recognition.
Preclinical Efficacy
Selective binding and cytotoxicity. CD19-ReTARGTPR mediated dose-dependent cytotoxicity against SEM B-ALL cells in the presence of anti-CMV CTLs (E:T = 1:1), whereas Mock-ReTARGTPR lacking CD19 specificity showed minimal background killing. Cytotoxicity increased proportionally with higher E:T ratios.
Across a broad panel of hematologic cancer cell lines, CD19-ReTARGTPR redirected anti-CMV CTLs to eliminate CD19-positive targets of diverse origins, including AML (Kasumi-1), B-ALL (SEM, Wil2-S), B-CLL (HG-3), mantle cell lymphoma (JeKo-1, Granta-519), and Burkitt lymphoma (Namalwa, Ramos, Z138). CD19 expression levels varied across this panel, with highest surface density observed in Namalwa, SEM, and Ramos cells. CD19-negative K562 and CEM cells remained unaffected, and IFN-γ secretion was selectively induced in the presence of CD19-positive targets but not CD19-negative K562 cells.
Importantly, CD19-ReTARGTPR also mediated robust elimination of primary CD19-positive cancer cells from five CLL patients, with cytotoxicity increasing proportionally with E:T ratio and exceeding background levels in all patient samples tested. Primary CLL cells from all five patients showed detectable CD19 expression.
Activity against low antigen density. Target antigen downregulation is a well-documented resistance mechanism in both CAR-T cell and BiTE therapies. To evaluate efficacy under these conditions, the authors generated CEM clones engineered to express graded CD19 densities---approximately 2,800 (CEM CD19+), 150,000 (CEM CD19++), and 950,000 (CEM CD19+++) molecules per cell, as quantified by BD QuantiBrite analysis.
CD19-ReTARGTPR maintained potent cytotoxicity across all expression levels, achieving comparable lysis of CEM CD19+, CEM CD19++, and CEM CD19+++ targets. By contrast, blinatumomab completely failed to mediate lysis of the low-expressor clone (CEM CD19+) even at high E:T ratios, and CD19-CAR-T cells achieved only ~60% killing against this clone despite robust activity against intermediate and high expressors. These findings are consistent with the established requirement of CAR-T cells for 100- to 1,000-fold higher antigen density than physiologic TCR-mediated activation.
Safety Profile: Cytokine Release and Effector Persistence
Attenuated cytokine secretion. Despite comparable target cell lysis across all three CEM clones and the SEM cell line, IFN-γ secretion induced by CD19-ReTARGTPR was approximately 100-fold lower than with blinatumomab and 400-fold lower than with CD19-CAR-T cells . This reduction was observed irrespective of target CD19 density, with the differential most pronounced against high-expressor targets (CEM CD19+++) where CD19-CAR-T cells elicited >3,500 pg/mL IFN-γ compared with <20 pg/mL for CD19-ReTARGTPR.
Multiplex cytokine profiling of supernatants from SEM co-cultures further revealed marked reductions in core CRS-associated mediators, most notably TNF-α, TNF-β, and IL-6, alongside comparable decreases in G-CSF, GM-CSF, IL-8, and oncostatin M. This muted cytokine signature suggests a reduced requirement for tocilizumab intervention and a lower CRS risk profile.
Minimal activation-induced cell death. Following co-culture with high-CD19-expressing targets (CEM CD19+++), CD19-CAR-T cells exhibited a substantial ~40% increase in effector cell apoptosis, with the magnitude of AICD correlating positively with target antigen density (~20-30% for CEM CD19+/++ versus ~40% for CEM CD19+++) (Figure 5C). In contrast, anti-CMV CTLs redirected by CD19-ReTARGTPR showed only a modest ~10% increase in apoptosis across all E:T ratios and target cell types, with no significant difference between CD19-negative CEM and CD19-expressing clones (Figure 5A). PBMCs activated by blinatumomab showed no detectable AICD under these conditions (Figure 5B), reinforcing that AICD is predominantly a concern for CAR-T cell approaches driven by nonphysiologic signaling.
Translational Considerations
CD19-ReTARGTPR may be particularly valuable for patients who relapse with low CD19 expression following CAR-T therapy---a common resistance mechanism. The reduced IL-6 and TNF-α signature raises the prospect of safer outpatient administration with diminished CRS monitoring requirements.
Several limitations warrant consideration. All data are currently derived from in vitro systems; in vivo validation in xenograft or humanized mouse models is pending. As with other CD19-directed modalities, long-term B-cell aplasia and hypogammaglobulinemia are anticipated on-target toxicities. Furthermore, the approach is restricted to HLA-B*07:02-positive, CMV-seropositive individuals, although the modular architecture permits substitution of alternative viral peptides and HLA alleles to broaden applicability. The global frequency of HLA-B*07:02 exceeds 5%, and CMV seroprevalence ranges from ~80% in Europe and North America to nearly 100% in Africa and Asia, suggesting that a substantial patient population could potentially benefit from this strategy.
Conclusion
CD19-ReTARGTPR represents a conceptually distinct approach to T-cell redirection against CD19-expressing malignancies. By leveraging pre-existing anti-CMV immunity and preserving physiologic TCR/pHLA-I activation, this fusion protein achieves effective tumor elimination while avoiding the supraphysiologic cytokine release and AICD that limit current CAR-T and BiTE therapies. If validated in vivo, this strategy could emerge as a lower-toxicity alternative or complement to existing CD19-targeted immunotherapies, particularly in settings of low antigen density or where effector cell longevity is paramount.
